Swimmers ear doesn't just affect swimmers – two ear doctors explain what you need to know about this painful condition
About 10% of Americans will experience swimmer's ear during their lifetimes. Adults are affected more commonly, and children only rarely, generally ages 5 to 12.
But you don't have to be swimming to get swimmer's ear. Go out jogging or walking, or do yardwork on a hot day, and moisture from perspiration can drip in your ear. However, the occurrence increases fivefold in swimmers – thus the reason the condition came to be called 'swimmer's ear.' It also occurs more frequently in tropical climates because of humidity and higher temperatures.
As doctors who specialize in ear problems, we are actively involved in research and clinical treatment for children and adults struggling with ear, nose and throat problems. Practicing in the state of Florida, we've certainly seen our share of patients with swimmer's ear.
Causes and symptoms of swimmer's ear
Swimmer's ear is an infection in the external ear canal, the tube leading from the ear opening to the eardrum. Typically, swimmer's ear occurs only in one ear, and sometimes the eardrum itself is affected. Moisture trapped in the canal leads to a break in the skin barrier and creates an opening for certain bacteria types to enter or existing ones to overgrow.
One of these culprits is the bacterium Pseudomonas aeruginosa, which is present in soil and water throughout the world. These bacteria favor moist areas, such as sinks, toilets, inadequately chlorinated swimming pools and hot tubs, as well as outdated or inactivated antiseptic solutions.
If you have the infection, you'll know it. Symptoms generally appear a few days after infection. The main symptom of swimmer's ear is severe pain and discomfort. It's particularly noticeable when the outer ear is tugged, or by touching the tragus – that's the small bump at the front of your ear. Other symptoms include itchiness inside the ear, redness, swelling and drainage. A feeling of fullness, or the perception of a plugged ear, may also occur, along with disturbed balance and temporary hearing loss.
Predisposition to swimmer's ear
Numerous factors can predispose someone to swimmer's ear. They include a narrow ear canal, and skin diseases such as eczema or psoriasis. In addition, individuals wearing ear plugs, ear buds or hearing aids may be at an increased risk. Diabetics may also be more prone to the infection.
Swimmer's ear can also come from something getting stuck inside the ear, excessive ear cleaning or contact with chemicals in hair dye or hairspray.
Diagnosis and treatment
Swimmer's ear is diagnosed after a health care provider has gathered a thorough history and examined the inside of the ear. The ear canal will typically look red, swollen and moist. There is also a possibility of fluid drainage or the appearance of scaly, shedding skin. Depending on the degree of swelling, the eardrum may be hard to see. A sample of fluid may be removed from the ear and sent to a lab to look for bacteria or fungus.
Eardrops are commonly used to treat swimmer's ear. These drops often contain antibiotics to kill the infection and steroids to stop the swelling.
One such eardrop is Ciprodex. It contains ciprofloxacin, an antibiotic, and dexamethasone, a powerful steroid. Patients will need to place about four to five drops in the infected ear canal twice a day for seven to 10 days.
Another commonly prescribed drop is Floxin, which contains an antibiotic but not a steroid. It is commonly prescribed in less swollen but still infected ears.
Other drop preparations include Cortisporin, which contains a commonly used combination of neomycin and polymyxin B, as well as hydrocortisone. However, neomycin is also damaging to the inner ear, so doctors nowadays often turn to Ciprodex or Floxin.
In some cases, the ear canal is too swollen for drops to reach the infected area, so the physician may place a wick or stent in the ear canal to keep it open. This will usually be left in place for three to five days until removed by the doctor, although occasionally the wick falls out once the swelling subsides. Usually, after 10 days the infection is resolved and the ear canal skin returns to normal.
Managing a persistent infection
Sometimes swimmer's ear may not resolve after seven to 10 days of treatment with eardrops. Oral antibiotics are typically recommended if the infection has spread beyond the ear canal or in patients with poorly controlled diabetes. Hospitalization for swimmer's ear is rarely necessary; however, complications that can occasionally lead to hospitalization include fever, worsening discharge, extensive narrowing of the ear canal or failure of previous treatments.
Among the precautions you can take to prevent swimmer's ear: Keep the ear canal dry. Tip your head to one side to help the water drain. Use a soft towel or cloth, or gently use a hair dryer near it. If the self-cleansing mechanism of the ear canal is impaired, then the ear canal should be cleansed by a physician.
Since most bacteria prefer a pH-neutral environment, reducing the pH in the ear canal can prevent bacterial overgrowth. A homemade liquid tincture can be mixed from a solution of half rubbing alcohol and half distilled white vinegar. The alcohol combines with the water in the ear and then evaporates. This removes the water while the acidity of the vinegar keeps bacteria from growing.
Two to three drops are usually sufficient and can be applied as a preventive measure soon after the ear has been exposed to moisture. This liquid solution is not a replacement for medical treatment of an actual ear infection and is meant to be used only in people who are prone to such infections because of prolonged or frequent exposure to moisture.
Also, it is important to differentiate swimmer's ear from a middle ear infection, the most frequent reason for the use of antibiotics in children under age 5. Middle ear infections are usually associated with a viral upper respiratory infection, and they are more often seen during fall and winter, when influenza and cold viruses are more prevalent.
This article is republished from The Conversation, a nonprofit, independent news organization bringing you facts and trustworthy analysis to help you make sense of our complex world. It was written by: Thomas Schrepfer, University of Florida and Rex Haberman, University of Florida
Read more:
Hearing loss: early signs of damage in young adults who regularly attend loud clubs and concerts
A pediatrician explains a spike in ear infections this summer after COVID-19 restrictions lifted
What is earwax?
The authors do not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and have disclosed no relevant affiliations beyond their academic appointment.
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
This Is The One "Superfood" You Should Always Eat At Breakfast, According To An Expert
From Apple Jacks to cheese omelettes, blueberry pancakes to leftover pizza, there are a zillion and one potential choices for breakfast these days. But some options are definitely more nutrient-rich than others. So what would a dietitian's No. 1 pick be? And how can we get more good stuff into our bodies first thing in the morning without sacrificing deliciousness? That's the question that we — Raj Punjabi and Noah Michelson, the hosts of HuffPost's Am I Doing It Wrong? podcast ― had for Lisa Moskovitz, a registered dietitian, certified dietitian-nutritionist and the CEO of NY Nutrition Group, when she dropped by our studio to offer her tips and tricks for doing breakfast better. Listen to the full episode here. Moskovitz's breakfast all-star is chia seeds, which are harvested from Salvia hispanica, a member of the mint family. Related: Related: 'It's a superfood because of all of the nutritional properties that it has, from fiber and magnesium to B vitamins and iron, and there's a little protein in there,' the author of The Core 3 Healthy Eating Plan told us. They also contain omega-3 fatty acids, which help keep our brains and hearts healthy and have been shown to reduce inflammation. 'It's great for regulating digestion,' Moskovitz added, 'so for people that struggle ... with constipation and regularities, chia seeds are a great source of insoluble and soluble fiber.' In fact, just one serving of chia seeds — typically two to three tablespoons — offers nearly 10 grams of fiber, which is one-third of the recommended daily intake for most people. Fiber not only helps with digestion by bulking and softening stools; it's been found to lower the risk for many dangerous health conditions, including heart disease, diabetes and some cancers. Chia seeds are also incredibly versatile and can be easily added to countless breakfast favorites to boost their nutritional benefits. 'You can sprinkle them in your yogurt, you can put them in your oatmeal, you can even sprinkle them on your avocado toast, in your eggs, in your coffee, and you can just take them in water,' Moskovitz suggested. 'You can soak them in your almond milk or dairy milk or any or oat milk and leave them in the fridge overnight, and that's a great grab-and-go.' By making tiny tweaks — including adding chia seeds or other nutrient-packed foods like nuts and fruit — to our tried and true breakfast go-tos, we can score more of what our bodies need without missing out on our morning favorites. 'Stop worrying about what to cut out and just think about what we can add in,' she advised. Moskovitz also chatted with us about the ideal time to eat breakfast, what to know before you eat another egg, the four things to add to every smoothie, and much more. Listen to the full episode wherever you get your podcasts. Make sure to subscribe to so you don't miss a single episode, including how to find love online or ; tips for , taking care of your teeth and ; secrets to ; how to ; shocking ; ; getting ; dealing with ; how to prevent ; boosting ; and much more. For more from Lisa Moskovitz, visit NY Nutrition Group and follow her on Instagram. Need some help with something you've been doing wrong? Email us at AmIDoingItWrong@ and we might investigate the topic in an upcoming article originally appeared on HuffPost. Also in Goodful: Also in Goodful: Also in Goodful:
Yahoo
an hour ago
- Yahoo
Northern California officials issue unsafe water alert, do not drink
( — A community in Northern California was issued an unsafe water alert and warned not to drink tap water because of possible bacterial contamination. On July 19, the Elk Creek Community Services District advised customers in Glenn County to use only bottled water for drinking, mixing baby formula, brushing teeth, washing dishes, making ice, and all other food preparation until further notice. Officials said a broken water main caused water pressure to drop below the minimum required, which would cause the water to be contaminated with coliform bacteria. Cliff jumper dies at Northern California lake after hitting water face-first 'We will inform you when tests show that the water is safe again,' ECCSD said in the advisory. 'We expect to resolve the bacteria contamination question within a few days.' Officials said the warning is a precautionary measure, and customers should not try to treat the water on their own. According to ECCSD, the water is safe for bathing and toilet use. For more information, customers can contact the ECCSD water plant operator, Jon Albertsen, at 707-489-1274 or the board president, Sharon Green, at 530-934-6588. Additionally, people who are concerned about their health can contact the Glenn County Public Health Department at 530-934-6588. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Solve the daily Crossword
Yahoo
an hour ago
- Yahoo
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
Novel preservative-free CBT-004 eye drop formulation demonstrates statistically significant improvements in conjunctival hyperemia and patient-reported symptoms with excellent safety profile IRVINE, Calif., July 21, 2025--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at View source version on Contacts Contact Information: Cloudbreak Pharma media@ Web: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data